Novo Nordisk's acquisition of the US-based biotech company for USD 3.3bn follows a two-year-long successful collaboration, and signals that more drug candidates from Dicerna's technology platform targeting Novo's focus areas could be on their way in the future, says Marcus Schindler, executive vice president and chief scientific officer at Novo Nordisk, to MarketWire.
The biotech company, which is based in Lexington, has specialized within RNA interference (RNAi), a technology where specific genes are suppressed before they can produce proteins that contribute to disease progression.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Key Account Manager, Europe and Asia 
2 Sales Representatives and Product Specialists 
(Senior) Drug Substance Specialist 
Project Manager & Scrum Master 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Biostatistician 
Client Talent Acquisition Specialist 
Biomarker Operations Lead 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Clinical Project Manager 
Director Global Engineering 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Strategic Procurement Manager, Direct Spend (Category Manager) 
IRT Manager, Clinical Drug Supply 
SAP System Specialist (Product Supply) – Business Application Services 
Production Director 
Director for innovative pre-clinical testing unit 
Senior Project Manager (GMP - Life Science)